HeimNTLA • NASDAQ
add
Intellia Therapeutics Inc
Við síðustu lokun
10,99 $
Dagbil
10,11 $ - 10,77 $
Árabil
9,25 $ - 34,87 $
Markaðsvirði
1,05 ma. USD
Meðalmagn
2,85 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 9,11 m. | -24,02% |
Rekstrarkostnaður | 30,50 m. | 3,73% |
Nettótekjur | -135,71 m. | -11,04% |
Hagnaðarhlutfall | -1,49 þ. | -46,15% |
Hagnaður á hvern hlut | -1,34 | 2,90% |
EBITDA | -142,16 m. | -10,36% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 658,11 m. | -23,01% |
Heildareignir | 1,17 ma. | -5,63% |
Heildarskuldir | 210,74 m. | 2,33% |
Eigið fé alls | 962,62 m. | — |
Útistandandi hlutabréf | 101,85 m. | — |
Eiginfjárgengi | 1,16 | — |
Arðsemi eigna | -30,61% | — |
Ávöxtun eigin fjár | -33,80% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -135,71 m. | -11,04% |
Handbært fé frá rekstri | -84,84 m. | 16,32% |
Reiðufé frá fjárfestingum | -7,71 m. | -109,70% |
Reiðufé frá fjármögnun | 82,19 m. | 330,28% |
Breyting á handbæru fé | -10,35 m. | -272,58% |
Frjálst peningaflæði | -35,80 m. | 44,08% |
Um
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Framkvæmdastjóri
Stofnsett
2014
Höfuðstöðvar
Vefsvæði
Starfsfólk
526
